Systematic review of clinical practice guidelines for kidney disease in China: application of the Appraisal of Guidelines Research and Evaluation-China
10.3760/cma.j.issn.1001-7097.2019.12.008
- VernacularTitle: 中国肾脏疾病临床实践指南现状的系统分析——中国临床实践指南评价体系的应用
- Author:
Chao YANG
1
;
Chao HUANG
2
;
Lili LIU
1
;
Rui CHEN
1
;
Jinwei WANG
1
;
Liqiang MENG
1
;
Luxia ZHANG
1
,
3
;
Hong ZHANG
1
;
Qiang WANG
2
;
Jicheng LYU
1
;
Minghui ZHAO
1
,
4
Author Information
1. Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing 100034, China
2. National Center for Medical Service Administration, National Health Commission, Beijing 100044, China
3. National Institute of Health Data Science at Peking University, Beijing 100191, China
4. Peking-Tsinghua Center for Life Sciences, Beijing 100871, China
- Collective Name:Evaluation and Selection of Clinical Practice Guidelines for Kidney Disease Working Group
- Publication Type:Journal Article
- Keywords:
Kidney diseases;
Evidence-based medicine;
Systems analysis;
Clinical practice guidelines
- From:
Chinese Journal of Nephrology
2019;35(12):929-936
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the quality of clinical practice guidelines for kidney diseases in China and provide reference for selecting suitable high-quality guidelines for primary care and developing standardized guidelines.
Methods:The China Guideline Clearinghouse, China Biology Medicine disc, VIP Database, Wanfang Database and CNKI, and other resources were searched from January 2013 to July 2018. In accordance with the criteria for inclusion and exclusion, the published guidelines for kidney diseases were screened. The Appraisal of Guidelines Research and Evaluation-China (AGREE-China) was used to systematically assess the current status of domestic guidelines for kidney diseases.
Results:A total of 18 guidelines for kidney diseases were included, covering different types of kidney disease such as glomerulonephritis, nephrotic syndrome, end-stage renal disease and other diseases. The overall score ranged from 30 to 68, with an average score of 47.3. The average scores of these guidelines were 20.1, 12.8, 0.5, 9.9 and 3.9 in five review fields including scientificity/rigorism, effectiveness/safety, economy, availability/feasibility, and conflicts of interest, respectively. Of these 18 guidelines, 8(44.4%) guidelines were strongly recommended, and 10(55.6%) guidelines were weakly recommended.
Conclusions:There are still deficiencies in scientificity/rigorism and economy in current guidelines for kidney diseases in China. The AGREE-China can be used as an evaluation tool for guidelines for kidney diseases in accordance with China's situation, while its practicability and feasibility still need further verification and improvement.
